[CAS NO. 135729-62-3] Palonosetronhydrochloride

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [135729-62-3]

Catalog

HY-A0021

Brand

MCE

CAS

135729-62-3

DESCRIPTION [135729-62-3]

Overview

MDL	MFCD07370072
Molecular Weight	332.87
Molecular Formula	C19H25ClN2O
SMILES	O=C1N(C[C@@]([H])(CCC2)C3=C2C=CC=C13)[C@@H]4CN5CCC4CC5.[H]Cl

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681.

Summary

Palonosetron hydrochloride is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). IC50 Value: Target: 5-HT Receptor Palonosetron is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy.

IC50 & Target

5-HT ₃ Receptor

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04912271	Fudan University	Chemotherapy-induced Nausea and Vomiting (CINV)	June 10, 2021	Phase 3
NCT00343460	Heron Therapeutics	Nausea and Vomiting\|Unspecified Adult Solid Tumor, Protocol Specific	June 2006	Phase 3
NCT00900757	Duke University\|Eisai Inc.	Malignant Glioma	August 2009	Phase 2
NCT02388750	Dr. Edward Chow\|Sunnybrook Health Sciences Centre	Nausea\|Vomiting	April 2015	Phase 2
NCT01481831	Shanghai Changzheng Hospital\|JiangSu Chia-Tai Tianqin Pharmacy Co.Ltd	Neoplasms\|Chemotherapy-Induced Nausea and Vomiting	July 2011	Phase 4
NCT03040726	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Helsinn Healthcare SA	Malignant Neoplasm\|Nausea\|Vomiting	May 3, 2017	Phase 2\|Phase 3
NCT02941913	Instituto Nacional de Cancer, Brazil	Postoperative Nausea and Vomiting	October 2016	Phase 4
NCT01339260	Helsinn Healthcare SA\|Parexel	Chemotherapy-Induced Nausea and Vomiting	April 2011	Phase 3
NCT01909856	Jiangsu Simcere Pharmaceutical Co., Ltd.	Cancer	October 2011	Phase 2
NCT03008213	Joseph Ma\|University of California, San Diego	Chemotherapy Induced Nausea Vomiting	January 2017	Phase 2
NCT01952626	Kyungpook National University Hospital	Morphine Adverse Reaction	April 2013	Not Applicable
NCT01370408	Northside Hospital, Inc.\|Blood and Marrow Transplant Group of Georgia	Chemotherapy-induced Nausea and Vomiting	February 2012	Phase 2
NCT00600353	University of Kansas Medical Center\|Eisai Inc.	Myeloma, Plasma-Cell\|Lymphoma, Malignant	October 2007	Phase 2
NCT00410488	M.D. Anderson Cancer Center\|Eisai Inc.	Sarcoma\|Nausea\|Vomiting	December 2006	Not Applicable
NCT01395901	Helsinn Healthcare SA	Postoperative Nausea and Vomiting	June 2011	Phase 3
NCT04533867	Bagcilar Training and Research Hospital	Nausea, Postoperative\|Vomiting, Postoperative\|Patient Reported Outcomes\|Pain, Postoperative\|Antiemetics	August 15, 2020
NCT02445872	Zhejiang University\|Merck Sharp & Dohme LLC	Chemotherapy-Induced Nausea and Vomiting\|Lung Cancer	December 2015	Phase 2
NCT03586817	Hospital Federal de Bonsucesso	Nausea and Vomiting, Postoperative	March 2, 2019	Phase 4
NCT02541019	Hospital Federal de Bonsucesso	Postoperative Nausea and Vomiting	October 2015	Phase 4
NCT02468323	Hospital de Base	PONV	October 2015	Phase 4
NCT02809378	Ajou University School of Medicine\|HK inno.N Corporation	PONV\|Palonosetron\|Anesthesia	June 2016	Phase 4
NCT00415103	PETHEMA Foundation\|Merck Sharp & Dohme LLC	Leukemia\|Lymphoma	November 2006	Phase 4
NCT01482468	Incheon St.Mary´s Hospital	Postoperative Nausea and Vomiting	March 2012	Not Applicable
NCT01018758	Gruppo Italiano Studio Linfomi	Chemotherapy-Induced Nausea and Vomiting\|Non Hodgkin´s Lymphoma	July 2006	Phase 2
NCT03606369	Instituto Nacional de Cancerologia de Mexico	Breast Neoplasm\|Antineoplastic Agents\|Antiemetics\|Quality of Life	November 5, 2015	Phase 2\|Phase 3
NCT01442376	Helsinn Healthcare SA	Chemotherapy-Induced Nausea and Vomiting	September 2011	Phase 3
NCT01568268	Samsung Medical Center\|HK inno.N Corporation	Laparoscopic Gynecologic, Abdominal, Other Surgery\|General Anesthesia	January 2012	Phase 3
NCT00359567	Taiho Pharmaceutical Co., Ltd.	Chemotherapy-Induced Nausea and Vomiting	July 2006	Phase 3
NCT00306735	Eisai Inc.\|Helsinn Healthcare SA	Multiple Myeloma	March 2006	Phase 2
NCT04563260	Ajou University School of Medicine	Gallbladder Diseases	October 7, 2020	Not Applicable
NCT02970643	Hee Jun Kim\|HK inno.N Corporation\|Chung-Ang University Hosptial, Chung-Ang University College of Medicine	Chemotherapy-induced Nausea and Vomiting	July 2016	Not Applicable
NCT02205164	Associazione Salentina Angela Serra	Chemotherapy Induced Nausea and Vomiting	October 2011	Phase 2
NCT03960151	Costantine Albany\|Tesaro, Inc.\|Hoosier Cancer Research Network	Germ Cell Tumor	May 2018	Phase 2
NCT01640340	Ohio State University Comprehensive Cancer Center	Malignant Neoplasm	January 2011	Not Applicable
NCT00952133	NYU Langone Health\|Eisai Inc.	PONV	July 2009	Phase 4
NCT02597907	Kyungpook National University Hospital	Postoperative Nausea and Vomiting	July 2014	Not Applicable
NCT02557035	Helsinn Healthcare SA\|PSI CRO	Chemotherapy-Induced Nausea and Vomiting	October 2015	Phase 3
NCT04507711	Seoul National University Bundang Hospital	Blood Coagulation Disorder	September 16, 2020	Not Applicable
NCT03148704	Cttq	Palonosetron	March 8, 2017
NCT00895245	University of Washington\|National Cancer Institute (NCI)	Nausea and Vomiting\|Stage III Squamous Cell Carcinoma of the Hypopharynx\|Stage III Squamous Cell Carcinoma of the Larynx\|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity\|Stage III Squamous Cell Carcinoma of the Nasopharynx\|Stage III Squamous Cell Carcinoma of the Oropharynx\|Stage IV Squamous Cell Carcinoma of the Hypopharynx\|Stage IV Squamous Cell Carcinoma of the Larynx\|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity\|Stage IV Squamous Cell Carcinoma of the Nasopharynx\|Stage IV Squamous Cell Carcinoma of the Oropharynx	February 2009	Phase 2
NCT00666783	Xijing Hospital	Chemotherapy-Induced Nausea and Vomiting		Phase 2
NCT01478165	Incheon St.Mary´s Hospital	Postoperative Nausea and Vomiting	September 2011	Not Applicable
NCT04592198	Xiamen LP Pharmaceutical Co., Ltd	Nausea With Vomiting Chemotherapy-Induced	October 1, 2020	Phase 2
NCT03578081	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Malignant Neoplasm	October 15, 2018	Phase 3
NCT00828295	Helsinn Healthcare SA	Postoperative Nausea and Vomiting	August 2008	Phase 3
NCT03674294	Sun Yat-sen University	Gastrointestinal Neoplasms\|Chemotherapy-induced Nausea and Vomiting	August 4, 2015	Phase 3
NCT00412425	M.D. Anderson Cancer Center\|Eisai Inc.	Melanoma	November 2006	Phase 1\|Phase 2
NCT05199818	Xiamen LP Pharmaceutical Co., Ltd	Chemotherapy-induced Nausea and Vomiting	March 1, 2022	Phase 3
NCT02625181	Vanderbilt University\|Vanderbilt University Medical Center	Postoperative Nausea and Vomiting	July 2016	Not Applicable
NCT00687011	Merck Sharp & Dohme LLC	Neoplasms\|Nausea\|Vomiting	October 10, 2006	Phase 4
NCT02744508	Yonsei University	Orthopedic Surgery	July 24, 2015	Not Applicable
NCT01650961	Seoul National University Hospital	Anesthesia, General\|Palonosetron	July 2012	Not Applicable
NCT00661674	Stanford University	Substance-Related Disorders	April 2008	Not Applicable
NCT01376297	Helsinn Healthcare SA\|Parexel	Chemotherapy-Induced Nausea and Vomiting	July 2011	Phase 3
NCT04060771	Universidade Federal Fluminense	Anesthesia\|Strabismus\|PONV	August 1, 2018	Phase 3
NCT00381862	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	Colorectal Cancer\|Nausea and Vomiting	June 2006	Phase 2
NCT01031498	M.D. Anderson Cancer Center\|Eisai Inc.	Acute Myelogenous Leukemia\|Chemotherapy-induced Nausea and Vomiting	September 2005	Phase 2
NCT01825733	Yonsei University	Postoperative Nausea and Vomiting	August 2011	Not Applicable
NCT02484911	First Affiliated Hospital of Harbin Medical University\|Harbin Medical University	Chemotherapy-induced Nausea and Vomiting	May 2015	Phase 3
NCT03204279	Helsinn Healthcare SA	Chemotherapy-induced Nausea and Vomiting (CINV)	August 31, 2017	Phase 2
NCT00553059	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Solvay Pharmaceuticals	Chemotherapy-induced Nausea and Vomiting\|Unspecified Adult Solid Tumor, Protocol Specific	May 2008	Phase 3
NCT04576390	Theodor Bilharz Research Institute\|Cairo University	Antiemetic\|Postoperative Nausea and Vomiting	October 24, 2020	Phase 4
NCT04308837	Icahn School of Medicine at Mount Sinai	Gastric Cancer\|Stomach Cancer	July 31, 2018	Phase 2
NCT00475085	Joseph Roscoe\|National Cancer Institute (NCI)\|University of Rochester	Nausea	December 2006	Phase 3
NCT02650479	Intarcia Therapeutics	Healthy Adult Male and Female Volunteers	January 2016	Phase 1
NCT01046240	Clinica Universidad de Navarra, Universidad de Navarra	Emesis	October 2009	Phase 1\|Phase 2
NCT00982995	University of Michigan Rogel Cancer Center	Nausea\|Vomiting\|Terminally Ill	November 2010	Phase 2
NCT03649230	Purdue Pharma, Canada	Chemotherapy-Induced Nausea and Vomiting	October 3, 2018
NCT00684463	Merck Sharp & Dohme LLC	Neoplasms\|Nausea\|Vomiting	April 11, 2007	Phase 4
NCT00636805	Duke University\|Eisai Inc.\|National Institute of Neurological Disorders and Stroke (NINDS)	Brain Cancer	May 2008	Phase 2
NCT00343863	University of Washington\|National Cancer Institute (NCI)	Male Breast Cancer\|Nausea and Vomiting\|Stage I Breast Cancer\|Stage II Breast Cancer\|Stage IIIA Breast Cancer	January 2006	Not Applicable
NCT03097588	OHSU Knight Cancer Institute\|Helsinn Therapeutics (U.S.), Inc\|Oregon Health and Science University	Malignant Neoplasm	April 27, 2017	Phase 2
NCT02203253	China Medical University, China\|The First Hospital of Liaoning Medical University\|The First Affiliated Hospital of Dalian Medical University\|The Second Affiliated Hospital of Dalian Medical University\|Liaoning Tumor Hospital & Institute\|Shengjing Hospital\|General Hospital of Shenyang Military Region\|Liaoyang Central Hospital\|Third People´s hospital Liaoyang\|Petrochemical General Hospital of Liaoyang city\|Anshan Tumor Hospital	Neoplasms	July 2014	Phase 3
NCT00967499	Eisai Inc.	Postoperative Nausea and Vomiting	July 13, 2009	Phase 2
NCT02135510	Amsterdam UMC, location VUmc\|Noordwest Ziekenhuisgroep\|Rijnstate\|Tergooiziekenhuizen locatie Hilversum\|Ziekenhuis Amstelland	Solid Tumors	June 2013	Phase 3
NCT03403712	Helsinn Healthcare SA\|George Clinical Pty Ltd\|The Physicians´ Services Incorporated Foundation	Chemotherapy-induced Nausea and Vomiting	March 16, 2018	Phase 3
NCT03817970	University of Colorado, Denver\|Memorial Sloan Kettering Cancer Center\|Rutgers University\|National Institute of General Medical Sciences (NIGMS)	Nephrotoxicity	June 26, 2019	Not Applicable
NCT01476280	Incheon St.Mary´s Hospital	Postoperative Nausea and Vomiting	May 2011	Not Applicable
NCT00903396	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Anal Cancer\|Carcinoma of the Appendix\|Colorectal Cancer\|Extrahepatic Bile Duct Cancer\|Gallbladder Cancer\|Gastric Cancer\|Gastrointestinal Carcinoid Tumor\|Liver Cancer\|Nausea and Vomiting\|Pancreatic Cancer\|Primary Peritoneal Cavity Cancer\|Small Intestine Cancer	September 2009	Phase 2
NCT01169805	Yonsei University	Laparoscopic Marsupialization of Renal Cyst	August 2010	Not Applicable
NCT00503386	Hangzhou Jiuyuan Gene Engineering Co. Ltd.,\|Sun Yat-sen University\|Tigermed Consulting Co., Ltd	Nausea\|Vomiting\|Chemotherapy	April 2006	Phase 2
NCT01363479	Helsinn Healthcare SA\|Parexel	Chemotherapy-Induced Nausea and Vomiting	July 2011	Phase 3
NCT04585412	Yung Shin Pharm. Ind. Co., Ltd.	Chemotherapy-induced Nausea and Vomiting, Prophylaxis	August 17, 2020	Phase 4
NCT03933605	Yeungnam University College of Medicine	Postoperative Nausea\|Postoperative Vomiting	July 10, 2017	Not Applicable
NCT02480088	Yonsei University	Postoperative Nausea and Vomiting	September 22, 2014	Phase 4
NCT05315999	Gerhild Becker\|University Hospital Freiburg	Nausea\|Vomiting\|Pain\|Advanced Cancer	May 2022	Phase 2
NCT02635828	Ohio State University\|Eisai Inc.	Postoperative Nausea and Vomiting	October 2009	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

H ₂ O : 100 mg/mL ( 300.42 mM ; Need ultrasonic)

DMSO : 3.33 mg/mL ( 10.00 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0042 mL	15.0209 mL	30.0418 mL
5 mM	0.6008 mL	3.0042 mL	6.0084 mL
10 mM	0.3004 mL	1.5021 mL	3.0042 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (300.42 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 0.33 mg/mL (0.99 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 0.33 mg/mL (0.99 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 0.33 mg/mL (0.99 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

1H-Benz[de]isoquinolin-1-one, 2-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-, hydrochloride (1:1), (3aS)-

1H-Benz[de]isoquinolin-1-one, 2-(1-azabicyclo[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-, monohydrochloride, [S-(R*,R*)]-

1H-Benz[de]isoquinolin-1-one, 2-(3S)-1-azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-, monohydrochloride, (3aS)-

RS 25259-197

Palonosetron hydrochloride

Aloxi

Onicit